Revolution Medicines Inc Stock
Revolution Medicines Inc Stock price
Key metrics
| Market capitalization | $7.13b |
| Enterprise Value | $5.66b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 7,653.34 |
| P/S ratio (TTM) P/S ratio | 9,630.05 |
| P/B ratio (TTM) P/B ratio | 4.19 |
| Revenue growth (TTM) Revenue growth | -97.16% |
| Revenue (TTM) Revenue | $740.00k |
Is Revolution Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
Revolution Medicines Inc Stock Analysis
Analyst Opinions
15 Analysts have issued a Revolution Medicines Inc forecast:
Analyst Opinions
15 Analysts have issued a Revolution Medicines Inc forecast:
Financial data from Revolution Medicines Inc
| Sep '24 |
+/-
%
|
||
| Revenue | 0.74 0.74 |
97%
97%
|
|
| Gross Profit | -11 -11 |
162%
162%
|
|
| EBITDA | -642 -642 |
78%
78%
|
EBIT (Operating Income) EBIT | -653 -653 |
77%
77%
|
| Net Profit | -567 -567 |
71%
71%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Revolution Medicines Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Revolution Medicines Inc Stock News
Company Profile
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.
| Head office | United States |
| CEO | Mark Goldsmith |
| Employees | 378 |
| Founded | 2004 |
| Website | www.revmed.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
